US005591767A

United States Patent [19]

Mohr et al.

[11] **Patent Number: 5,591,767**

[45] **Date of Patent: * Jan. 7, 1997**

[54] **LIQUID RESERVOIR TRANSDERMAL PATCH FOR THE ADMINISTRATION OF KETOROLAC**

[75] Inventors: **Judy M. Mohr**, Menlo Park; **Richard W. Baker**, Palo Alto; **Lisa A. Nakaji**, San Jose, all of Calif.

[73] Assignee: **Pharmetrix Corporation**, Menlo Park, Calif.

[*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. No. 5,589,498.

[21] Appl. No.: **470,659**

[22] Filed: **Jun. 6, 1995**

Related U.S. Application Data

[63] Continuation of Ser. No. 10,256, Jan. 25, 1993, abandoned.

[51] **Int. Cl.**[6] **A61K 31/40**; A61K 9/70

[52] **U.S. Cl.** **514/413**; 424/449

[58] **Field of Search** 514/413; 424/449

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,797,494	3/1974	Zaffaroni	128/268
4,031,894	6/1977	Urquhart et al.	128/268
4,089,969	5/1978	Muchowski et al.	424/274
4,460,372	7/1984	Campbell et al.	604/897
4,588,580	5/1986	Gale et al.	424/21
4,615,699	10/1986	Gale et al.	604/897
4,818,541	4/1989	Sanderson	424/448
4,839,174	6/1989	Baker et al.	424/447
4,906,463	3/1990	Cleary et al.	424/78
4,908,027	3/1990	Enscore et al.	604/890.1
4,910,205	3/1990	Kogan et al.	514/290
4,915,950	4/1990	Miranda et al.	424/448
4,956,181	9/1990	Bayer et al.	424/448
4,992,445	2/1991	Lawter et al.	514/279
5,008,110	4/1991	Benecke et al.	424/448
5,049,386	9/1991	Eppstein et al.	424/427
5,069,909	12/1991	Sharma et al.	424/449
5,091,182	2/1992	Ong et al.	424/400
5,114,946	5/1992	Lawter et al.	514/279
5,124,157	6/1992	Colley et al.	424/448
5,519,046	5/1996	Noda et al.	514/413

FOREIGN PATENT DOCUMENTS

4-321624	11/1992	Japan .
9103998	4/1991	WIPO .
WO93/04677	3/1993	WIPO .
WO93/24114	9/1993	WIPO .

OTHER PUBLICATIONS

Baker, R. W. *Controlled Release of Biologically Active Agents*, John Wiley & Sons, NY pp. 4–10 (1987).

Jamali et al. *J. of Pharmaceutical Sciences* 789 695–714 (1989).

Campbell, D. B. *European J. of Drug Metabolism and Pharmacokinetics*15 109–125 (1990).

Guzman, et al. *J. Med. Chem.* 29 589–591 (1986).

Mroszczak et al. *Clin. Pharmacology & Therapeutics*49 126 (1991).

Stinson *C&EN*46–79 (Sep. 28, 1992).

Yu, et al., "Percutanteous Absorption of Nicardipine and Ketorolac in Rehsus Monkeys," Pharmaceutical Research, vol. 5, No. 7, 1988, pp. 457–462.

Greenwald, "Ketorolac: An Innovative Non–Steroidal Analgesic," Drugs of Today, vol. 28, No. 1, 1992, pp. 41–61.

Pfister, et al., "Permeation Enhancers Compatible with Transdermal Drug Delivery Systems—Part I . . . ," Phar. Tech. Sep. 1990, pp. 132–140.

Brocks et al., *Medline Abstract*No. 93092511, 1992.

Primary Examiner—Marianne M. Cintins
Assistant Examiner—William R. A. Jarvis
Attorney, Agent, or Firm—Townsend and Townsend and Crew

[57] **ABSTRACT**

The invention is directed to a patch for the transdermal delivery of the racemic form or the active enantiomer of the analgesic ketorolac. The transdermal patch is capable of delivering therapeutically effective doses of the drug for a period of 12 hours or more. The patch is capable of delivering the racemate of ketorolac at a flux rate of 40 $\mu g/cm^2 \cdot hr$ or more, and of the active enantiomer at a flux rate of 20 $\mu g/cm^2 \cdot hr$ or more.

16 Claims, 3 Drawing Sheets